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Abstract
Aims/hypothesis MicroRNAs regulate a broad range of
biological mechanisms. To investigate the relationship
between microRNA expression and type 2 diabetes, we
compared global microRNA expression in insulin target
tissues from three inbred rat strains that differ in diabetes
susceptibility.
Methods Using microarrays, we measured the expression
of 283 microRNAs in adipose, liver and muscle tissue from
hyperglycaemic (Goto–Kakizaki), intermediate glycaemic
(Wistar Kyoto) and normoglycaemic (Brown Norway) rats
(n=5 for each strain). Expression was compared across
strains and validated using quantitative RT-PCR. Further-
more, microRNA expression variation in adipose tissue was
investigated in 3T3-L1 adipocytes exposed to hyperglycae-
mic conditions.
Results We found 29 significantly differentiated micro-
RNAs (padjusted<0.05): nine in adipose tissue, 18 in liver
and two in muscle. Of these, five microRNAs had
expression patterns that correlated with the strain-specific
glycaemic phenotype. MiR-222 (padjusted=0.0005) and
miR-27a (padjusted=0.006) were upregulated in adipose
tissue; miR-195 (padjusted=0.006) and miR-103 (padjusted=
0.04) were upregulated in liver; and miR-10b (padjusted=
0.004) was downregulated in muscle. Exposure of 3T3-L1
adipocytes to increased glucose concentration upregulated
the expression of miR-222 (p=0.008), miR-27a (p=0.02)
and the previously reported miR-29a (p=0.02). Predicted
target genes of these differentially expressed microRNAs
are involved in pathways relevant to type 2 diabetes.
Conclusion The expression patterns of miR-222, miR-27a,
miR-195, miR-103 and miR-10b varied with hyperglycae-
mia, suggesting a role for these microRNAs in the
pathophysiology of type 2 diabetes, as modelled by the
Gyoto–Kakizaki rat. We observed similar patterns of
expression of miR-222, miR-27a and miR-29a in adipocytes
as a response to increased glucose levels, which supports our
hypothesis that altered expression of microRNAs accom-
panies primary events related to the pathogenesis of type 2
diabetes.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that
bind to regulatory sites of target mRNA and modify their
expression, either by translational repression or target
mRNA degradation, resulting in decreased protein produc-
tion. MiRNA–mRNA targeting is achieved through both
perfect and imperfect sequence alignment mechanisms. A
single miRNA may potentially regulate the expression of
several hundred genes. MiRNAs are increasingly recog-
nised as being involved in a broad range of biological
functions [1] and are known to be expressed in a tissue-
specific manner [2]. A growing body of evidence implicates
miRNAs in type 2 diabetes and pathophysiological ele-
ments of the cardiometabolic syndrome characterised by
hyperglycaemia (reviewed by Krutzfeldt and Stoffel [3]).
MiRNAs are required for pancreatic development [4], the
regulation of glucose-stimulated insulin secretion [5, 6] and
amino acid catabolism [7]. They are also involved in many
functional aspects of insulin target tissues, such as
adipocyte differentiation [8], myogenesis and myoblast
differentiation [9] and fatty acid synthesis in hepatocytes
[10].
MiRNA profiling using microarray technology has
recently been developed and applied to the study of a
variety of conditions [11, 12]. To date, only one study has
investigated miRNA expression in the context of type 2
diabetes [13], using the Goto–Kakizaki (GK) rat, a model
of spontaneous, lean type 2 diabetes [14]. Fifteen miRNAs
were found to differ in expression by more than 1.5-fold
between GK and Wistar control rats in skeletal muscle. As
global miRNA expression was investigated in only one
tissue and only in small samples (two rats per group),
further research in this area is needed.
Animal models offer great advantages for expression
studies, as their homogeneous genetic background and
controlled environment decrease the variability of gene
expression levels among colony members. A number of
polygenic animal models are available for type 2 diabetes
studies [15], including the widely studied GK strain. The
GK strain was derived by selectively breeding outbred
Wistar rats that spontaneously developed glucose intoler-
ance [14] and is a particularly good model for type 2
diabetes. The defects of these rats include glucose-
stimulated insulin secretion, peripheral insulin resistance,
stable fasting hyperglycaemia and hyperinsulinaemia,
which can be detected as early as 2–4 weeks of age [14, 16].
Additionally, the GK strain is non-obese and consequently
not affected by the confounding risk factors for type 2
diabetes introduced by obesity.
Given the critical roles miRNAs are suggested to play in
several aspects of glucose homeostasis, we hypothesised
that miRNA expression profiles of insulin target tissues
differ between hyperglycaemic and normoglycaemic status.
We employed microarray technology to generate miRNA
expression profiles in adipose tissue, liver and skeletal
muscle from GK rats, and compared these with expression
profiles from normoglycaemic, genetically related Wistar
Kyoto (WKY) rats, and normoglycaemic, genetically
distant Brown Norway (BN) rats, which are extensively
used to study genetic determinants of type 2 diabetes
phenotypes in F2 hybrids and congenic strains [17].
Phenotypic data for these strains, including fasting glucose
levels, show that the WKY strain has an intermediate
phenotype relative to GK and BN strains. Therefore, we
aimed to identify miRNAs showing differential expression
across strains, and specifically those with intermediate
expression levels in WKY rats. Predicted target genes of
differentially expressed miRNAs were identified and their
biological functions assessed using bioinformatics tools
(see Fig. 1 for an outline of the study design).
Methods
Research design and methods Four-month-old male rats
from GK (n=5), WKY (n=5) and BN (n=5) colonies were
fed with standard laboratory chow pellets (B&K Universal,
Hull, UK) and kept on a 12 h light/12 h dark cycle. Animal
procedures were carried out in accordance with UK Home
Office and institutional guidelines. GK and BN strains were
obtained from Oxford colonies (GK/Ox and BN/Ox) and
WKY rats from a commercial supplier (Harlan, Bicester,
UK). Fasting glycaemia was determined in representative
animals from the GK (n=8), BN (n=4) and WKY (n=5)
colonies after a 16–18 h fast, using an intraperitoneal
glucose tolerance test (IPGTT) [18]. Plasma concentrations
of glucose were determined using diagnostic kits (ABX,
Shefford, UK) on a Cobas Mira Plus automatic analyser
(ABX).
Liver, white adipose tissue (retroperitoneal fat pad) and
skeletal muscle (soleus) samples were obtained from each
of the 15 rats. Total RNA was then extracted from
homogenised tissue samples using TRI Reagent (Sigma,
Gillingham, UK) in accordance with the manufacturer’s
instructions. RNA quality was assessed using a spectro-
photometer (NanoDrop; Labtech International, Ringmer,
UK) and a Bioanalyzer 2100 (Agilent, South Queensferry,
UK). RNA was generally of high quality (average 260/280
1100 Diabetologia (2010) 53:1099–1109ratio 2.13 and average 260/230 ratio 1.83). Following RNA
quality control steps, 15 muscle samples (GK=5, BN=5 and
WKY=5), 14 fat samples (GK=4, BN=5 and WKY=5) and
13 liver samples (GK=4, BN=5 and WKY=4) were used.
Pancreatic tissue was not analysed in this study because of the
difficulty of extracting total RNA from pancreatic beta cells,
the number of which is significantly reduced in GK animals.
LNA-based miRNA microarray MiRNA profiling of liver,
fat and skeletal muscle samples was performed using the
locked nucleic acid (LNA mercury [19]) microarray from
Exiqon (Vedbaek, Denmark), which contains probes for 239
rat-specific miRNAs (based on mirBASE v8.1). Briefly,
2 μg of total RNA from experimental samples and from a
common reference rat sample were labelled in separate
reactions with Hy3 and Hy5 (Exiqon) fluorescent labels
respectively. Each pair of labelled experimental and refer-
ence samples was combined, denatured and hybridised to the
miRCURY LNA Array v.8.1 (Exiqon). This array contains
four replicates of each of the 239 rat miRNA probes as well
as spike-ins, negative controls and proprietary Exiqon
miRNA probes. Hybridisation was performed according to
the miRCURY LNA array manual using a Tecan HS4800
hybridisation station (Tecan, Männedorf, Germany). Low-
and high-stringency washes were carried out to minimise
non-specific hybridisation and the microarrays were then
dried. Images were acquired using an Axon GenePix 4000B
scanner (Axon Instruments-MDS, Sunnyvale, CA, USA) and
GenePix software (Sunnyvale, CA, USA).
Microarray data processing Raw intensity data were read
into the R statistical package [20] for further processing
using the ‘marray’ and ‘limma’ [21] libraries from
BioConductor [22]. Data were background-corrected using
negative control probes on the array to estimate background
signal. Probes were considered expressed in a given sample
when the intensity exceeded a threshold equal to the
median background (across all samples) + 2 SD units.
These data were then used to identify probes detected in at
least one of the three tissues; a probe was considered
expressed in a tissue if the median intensity exceeded the
background threshold. The data were normalised using the
locally weighted scatterplot smoothing (LOESS) regression
algorithm within each array, to adjust for any intensity-
dependent dye bias. Because of the expected differences in
miRNA expression between tissues, between-array normal-
isation was not performed. Inspection of box plots of the
M-ratios (log [experimental/reference]) showed that all
arrays for a given tissue had comparable distributions.
Rat-specific miRNAs that were expressed above back-
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Fig. 1 Outline of study design
and results
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subsequent analyses (n=152). Differential expression be-
tween tissues was calculated using functions in the limma
package, using data from all three strains (adipose tissue,
n=14; liver, n=13; muscle, n=14).
Then, data for each tissue were analysed for differential
expression between strains, again using limma. All results
of expression analysis were corrected for multiple testing
using the false discovery rate (FDR) method of Hochberg
and Benjamini [23] and FDR-adjusted p values <0.05,
corresponding to an FDR of 5%, were considered significant.
Direct miRNA quantification Validation of miRNA expres-
sion data for five miRNAs (miR-222, miR-103, miR-27a,
miR-195, miR-10b) by quantitative RT-PCR was performed
using total RNA from the 42 rat samples studied and
microRNA specific primers (Applied Biosystems [ABI],
Warrington, UK). Briefly, reverse transcription was carried
out in a total reaction volume of 15µl containing 5µl total
RNA (concentration 10 ng/µl), 3µl of reverse transcription
primer, 1.50µl of 10× RT buffer, 1.00µl MultiScribe
Reverse Transcriptase (50 U/µl), 0.15µl of 100 mmol/l
dNTPs (with dTTP), 0.19µl of RNase Inhibitor, 20 U/µl
and 4.16µl of nuclease-free water (all reagents supplied by
ABI). Reactions were incubated according to the manufac-
turer’s recommendations. Quantitative RT-PCRs were per-
formed in triplicate; the 10µl PCR reaction contained
1.33 µL reverse transcription product, 10µl 2× PCR Master
Mix, 1µl microRNA primer (ABI) and 7.67µl of nuclease-
free water. The reactions were incubated at 95°C for
10 min, followed by 40 cycles of 95°C for 15 s and 60°C
for 35 s. The highly conserved and universally expressed
snoRNA and 4.5 S RNA (H-rat) were used as normalising
endogenous controls in the qRT-PCR. Fold changes (FC)
in expression were calculated using the 2ΔΔCt method
[24].
Exposure of 3T3-L1 adipocyte cells to altered glucose
concentration We cultured 3T3-L1 fibroblasts (obtained
from ECACC (European Collection of Cell Cultures,
Salisbury, UK) in DMEM (containing 25 mmol/l glucose)
supplemented with 4 mmol/l glutamine and 10% calf serum
in addition to penicillin (100 U/ml) and streptomycin
(100 μg/ml) in humidified air at 37°C and 5% CO2.T w o
days after confluence, cells were differentiated by replacing
calf serum with 10% FBS and addition of 250 nmol/l
dexamethasone, 0.5 mmol/l 3-isobutyl-1-methylxanthine
(IBMX) and 100 nmol/l insulin to the growing medium.
After 2 days, cells were placed in DMEM containing
4 mmol/l glutamine, 10% FBS and 100 nmol/l insulin for two
more days. Following differentiation, cells were maintained in
DMEM containing 5 mmol/l glucose plus 4 mmol/l glutamine
and 10% FBS for an additional 2 days to recover at a low
glucose concentration and subsequently incubated for 24 h
with 5, 10, 15, 20 or 25 mmol/l glucose. Four biological
replications of this glucose stimulation experiment were
carried out. Total RNA was extracted using the miRNeasy
Mini Kit (Qiagen, Crawley, UK). Expression levels of miR-
222, miR-27a and the previously reported miR-29a (used
here as a positive control) were measured by qRT-PCR as
above, using microRNA specific primers (ABI) on the Bio-
Rad (Bio-Rad, Hemel Hempstead, UK) platform (PCR
reactions were run in triplicate). MiRNA expression was
normalised to the expression of the mouse controls
snoRNA202 and snoRNA234. Fold changes in expression
were calculated using the 2ΔΔCt method [24] by comparing
miRNA expression at 10, 15, 20 and 25 mmol/l with
expression at baseline (5 mmol/l). Analysis of variance was
used to compare differences in the mean values across all
glucose exposures.
In silico functional profiling of target genes Potential
miRNA target genes were identified and retrieved using
the algorithms implemented by the Sanger microRNA
database [25] and by TargetScan 4.2 [26]. Biological gene
annotation was generated using GENECODIS [27]. The
GENECODIS algorithm uses the hypergeometric distribu-
tion to determine whether individual pathways or combi-
nations of pathways are significantly overrepresented
among the genes of interest. The p values computed for
each pathway were adjusted using the FDR method of
Hochberg and Benjamini [23] to control the false discovery
rate, and corrected p values <0.01 were considered
significant.
Results
Characteristics of GK, BN and WKY rats To avoid possible
long-term modification of gene expression (including
miRNAs), which might be caused by intervention during
glucose tolerance testing (in particular the use of anaesthe-
sia), phenotyping was not performed in the same rats used
in this experiment, but in 4-month-old male rats represen-
tative of the GK (n=8), BN (n=4) and WKY (n=5)
colonies (see Electronic supplementary material [ESM]
Fig. 1). Cumulative glycaemia was significantly increased
in GK vs BN (p<0.001), GK vs WKY (p<0.001) and
WKY vs BN (p<0.05; ESM Fig. 1). An IPGTT showed a
significant increase in glycaemia in response to glucose
stimulus measured over 120 min, again with significant
differences between the strains (ESM Fig. 1). Although
WKY animals are normoglycaemic, they have plasma
glucose levels and cumulative glycaemia higher than those
of BN rats but lower than those of GK rats, placing WKY
animals at an intermediate phenotypic level (ESM Fig. 1).
1102 Diabetologia (2010) 53:1099–1109These phenotypic data are a reasonable assessment of the
glycaemic status of the rats used in this study, as they were
of the same age and from the same colonies. In addition,
several studies have reported increases in postprandial
plasma glucose, insulin levels and fasting plasma glucose
in GK rats starting a few weeks after birth [14, 28, 29].
MiRNA expression differs between insulin target tissues
MiRNA expression was characterised using the Exiqon
microarray platform in 13 liver, 15 muscle and 14 adipose
tissue samples that passed quality control tests (from a total
of 15 samples per tissue). Unsupervised hierarchical
clustering showed that each tissue had a distinct miRNA
expression profile (Fig. 2a). Of the 239 miRNA probes
evaluated, 152 were expressed over background in at least
one of the tissues, with 112 expressed in all three (Fig. 2b).
Among the miRNAs detected in only one of three tissues
studied were several with known tissue specificity, such as
miR-1,miR-206and miR-133 inmuscleand miR-122inliver
(ESM Table 1). The vast majority of miRNAs (123/152,
81%) showed statistically significant differences in expres-
sion (adjusted p<0.05) between at least one pair of tissues,
all with greater than 1.5-fold change (ESM Table 1). These
results highlight the tissue-dependent pattern of miRNA
expression.
MiRNA expression differs between diabetic and normoglycaemic
rat strains Analysis of differential expression between the
three rat strains using ANOVA revealed 29 significant
miRNAs (adjusted p<0.05). Of these, nine were observed
in adipose tissue, 18 in liver and two in muscle (Table 1;
ESM Fig. 2). Pairwise comparisons between strains (GK/
BN, BN/WKY and GK/WKY) were also carried out to
confirm the origin of the differences detected in the
ANOVA analysis (Table 1). The expression levels of five
miRNAs corresponded approximately to a linear relation-
ship between the glycaemic phenotypes of the three strains.
These were: miR-222 and miR-27a in adipose tissue (both
with BN<WKY<GK); miR-195 and miR-103 in liver (both
with BN<WKY<GK); and 10b in skeletal muscle
(BN>WKY>GK; Fig. 3). In liver, miR-191 was more
highly expressed in the GK rats than in either of the
normoglycaemic strains (GK>BN∼WKY), while miR-200a
had higher expression in the normoglycaemic strains
(BN∼WKY>GK; ESM Fig. 2). While these patterns may
be of biological interest (ESM Fig. 2), possibly reflecting
threshold effects of miRNA expression in relation to the
phenotype, we decided to focus on the five miRNAs with
an approximately linear relationship in expression levels
between strains.
Validation of differential expression between hyperglycaemic
and normoglycaemic rats The five miRNAs (miR-222,
miR-27a, miR-195, miR-103, miR-10b) with expression
patterns consistent with glycaemic status (GK<WKY<BN
or GK>WKY>BN) were selected for validation using the
same samples as in the microarray study. Relative levels of
expression across all strain comparisons for miR-222 in
adipose tissue and miR-103 in liver were validated by qRT-
PCR (Fig. 4). However, inconsistent results between array
and quantitative RT-PCR data were obtained for at least one
112
1 14
44 9
8
Adipose tissue Liver
Skeletal muscle
a
b
Liver Fat Muscle
Fig. 2 miRNA expression was specific in insulin target tissues from
GK, WKY and BN rats. a Unsupervised hierarchical clustering
analysis for expression of 152 miRNAs differentiated samples by
tissue. Each row represents an miRNA and each column a tissue
sample. Colours represent relative intensity of the detected signal in
each sample, red representing high expression and green representing
low expression. b Summary of miRNA expression across three insulin
target tissues (adipose tissue, liver and skeletal muscle) for 152
miRNAs detected above background levels
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1104 Diabetologia (2010) 53:1099–1109of the three possible strain comparisons for mir-27a in
adipose tissue, miR-195 in liver and miR-10b in muscle
(Fig. 4). It was notable that miR-222 showed the greatest
expression differences between strains, and was the most
successful validation. Thus, the modest fold changes could
be one explanation for the relatively poor validation rate,
which we have estimated at 60% (nine replicated fold
changes out of 15 comparisons). However, our results with
respect to validation are in agreement with other studies
that have shown the success of qRT-PCR, as a validation
tool for miRNA expression, to range between 50 and 100%
[30, 31]. The fold change detected in the qRT-PCR
experiment was much greater than that in the microarray
experiment; for miR-222 (4.8-fold increase [GK/BN] in
adipose tissue compared with a 2.4-fold change in the
microarray experiment), this may reflect the higher sensitivity
and larger dynamic range of quantitative RT-PCR, and has
been observed in other studies [32].
MicroRNA expression increases in response to hyperglycaemia
in adipocytes Exposure of 3T3-L1 adipocytes to increasing
concentrations of glucose (10, 15, 20 and 25 mmol/l)
resulted in an overall overexpression of miR-222, miR-27a
and miR-29a when compared with baseline (5 mmol/l).
MiR-27a expression declined initially (FC=0.76) at
10 mmol/l and then increased to values ranging between
1.29 and 1.4 (ANOVA, p=0.023). MiR-222 was initially
overexpressed at 10 (FC=1.27), 15 (FC=2.01) and 20
(FC=1.79) mmol/l of glucose. At the highest concentration
of glucose (25 mmol/l), the expression of miR-222 fell below
expressionatthebaseline(FC=0.8;ANOVA,p=0.0084). The
expression of miR-29a (our positive control) followed a pattern
similar to that presented by miR-222 but with a more gradual
decline towards higher glucose levels and never reaching
expression below the baseline level (FC=1.32 at 10 mmol/l,
FC=1.96 at 15 mmol/l, FC=1.49 at 20 mmol/l and FC=1.69 at
25 mmol/l; ANOVA, p=0.023; Fig. 5).
In silico functional profiling To gain insight into the
potential roles of the miRNAs that followed the observed
glycaemic phenotype between the three strains, a list of
potential gene-target transcripts was generated for miR-222,
miR-27a, miR-195, miR-103 and miR-10b. Predicted target
genes for these five miRNAs were identified using two
algorithms: miRanda and TargetScan, which produced 3,371
and 1,229 unique targets, respectively. Surprisingly, there was
no overlap between these two lists, highlighting the current
difficulty in inferring likely downstream effects of altered
miRNA expression. Each list was then profiled by querying
the annotated Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway database using GENECODIS [27]a n d
pathways significant in both analyses are reported. The genes
predicted to be targets of these miRNAs were significantly
enriched (FDR, adjusted p<0.01) for a number of signalling
pathways related to glucose homeostasis. Among the top-
ranking pathways in each analysis were the mitogen-
activated protein kinase (MAPK) signalling pathway, the
insulin signalling pathway and the gonadotropin-releasing
Fig. 3 Box plots of expression in strains GK, WKY and BN (relative
to a common reference) for five miRNAs whose expression was
consistent with glycaemic status. The pattern GK>WKY>BN was
observed for miR-27a (a) and miR-222 (b) in adipose tissue, and for
mir-103 (c) and miR-195 (d) in liver, whereas GK<WKY<BN was
observed for miR-10b in muscle (e). Circles represent outliers
Diabetologia (2010) 53:1099–1109 1105hormone signalling pathway (ESM Table 2). As miR-222
was validated both biologically and technically, a similar
approach was used to query the miRanda and TargetScan
lists of predicted target genes of this specific miRNA.
Among the significant pathways overlapping between the
two predictions, we observed the MAPK signalling pathway
(ESM Table 3).
Discussion
There isincreasingevidence that miRNAs playa roleinmany
aspects of metabolism and glucose homeostasis, and hence
may be involved in the pathogenesis of disorders such as type
2 diabetes. In this study we used microarrays to obtain global
expression profiles of miRNAs in three insulin target tissues
from hyperglycaemic rats (GK) and compared them with
expression profiles from controls derived from genetically
related (WKY) and genetically distant (BN) strains (for study
design and data breakdown, see Fig. 1).
Phenotypic data indicated that the WKY rats represent
an intermediate glycaemic phenotype between hypergly-
caemic GK rats and normoglycaemic BN rats (ESM Fig. 1).
We therefore focused on five miRNAs with relative
expression levels correlating with glycaemic status: miR-
222 and miR-27a are upregulated with hyperglycaemic
status in adipose tissue, miR-195 and miR-103 are
upregulated in liver, and miR-10b is downregulated in
skeletal muscle. Thus, four of the miRNAs showed highest
expression in GK and lowest in BN, while one showed the
reverse pattern. These five miRNAs showed a wide range
of expression levels in different tissues (averaged across
strains) and relative to each other (ESM Table 1). With the
exception of miR-27a, these miRNAs were expressed at
their highest levels in adipose tissue and lowest levels in
liver. Indeed, miR-222, miR-27a and miR-10b were only
expressed close to background levels in liver. Interestingly,
each of the five miRNAs showed the significant pattern in
only one of the three tissues studied, i.e. relative expression
Fig. 5 Relative changes in expression of miRNAs in 3T3-L1
adipocytes following stimulation with glucose. Fold changes in
expression of a miR-29a, b miR-222 and c miR-27a in response to
exposure of 3t3-L1 adipocytes to glucose 5, 10, 15, 20 and 25 mmol/l for
24 h. MicroRNA expression was assayed by qRT-PCR. Fold changes
were calculated using the 2ΔΔCt method and are relative to baseline
expression at 5 mmol/l. Error bars represent the standard deviation
Fig. 4 Signal intensity ratios between strains GK, WKY and BN for
array data (a) and quantitative RT-PCR (b) for miR-222 and miR-27a
in adipose tissue, miR103 and miR-195 in liver and miR-10b in
muscle. a Microarray log-ratio intensities for array data for each
sample relative to the common reference. Positive values indicate
higher expression in the experimental sample relative to the common
reference, and vice versa for negative values. Error bars show the SE.
The larger the mean log-ratio for a given strain, the more highly
expressed the corresponding miRNA. b Expression of miRNAs
detected using qRT-PCR. Data are presented as the inverse of the Ct
score. Columns indicate expression relative to the control genes
(snoRNA and 4.5S RNA) and error bars show the SE
1106 Diabetologia (2010) 53:1099–1109between strains differed between tissues for the same
miRNA. This may indicate that the changes in miRNA
expression in a given tissue relate to particular processes
occurring in that tissue, rather than to a general dysregu-
lation of miRNA expression. The inclusion of a strain with
an intermediate phenotype offered increased sensitivity in
detecting miRNAs that vary coordinately with the hyper-
glycaemic phenotype, as different sets of miRNAs were
identified as differentially expressed when the GK strain
was compared with BN or WKY separately (see Compar-
ison columns in Table 1). The most dramatic changes were
observed for miR-222 in adipose tissue (BN<WKY<GK),
and were confirmed both by qRT-PCR and exposure of
adipocytes to increased glucose levels in vivo to be
significantly correlated with the hyperglycaemic phenotype.
Upregulation of miR-222 has been shown to be involved in
cell cycle regulation through its control of cyclin-dependent
kinase inhibitor (p27
Kip1) expression [33, 34]. MiR-222
expression was highest in the hyperglycaemic GK strain,
and in view of microRNA’s regulatory role we would
expect the expression of its target genes to be affected in
GK adipose tissue as a result. Although not included in the
design or the scope of this study, direct control of target gene
expression exerted by miRNAs may be established through
functional studies that evaluate correlations with mRNA and
protein levels [35, 36].
Comparison of miRNA expression between the two
normoglycaemic strains (BN vs WKY) in the present study
showed significant differences in the expression levels of 30
out of 152 (∼20%) detected miRNAs, with modest fold
changes. These changes could reflect the strong genetic
divergence between WKY and BN strains [37]a sw e l la s
signatures of physiological features that characterise these
strains; for example, the WKY strain shows resistance to
mammary cancers, exhibits exaggerated neuroendocrine and
behavioural responses to stress and is used as a model of
depression [38, 39]. Further evidence of possible strain
effects that might interfere with the interpretation of micro-
RNA expression data arises from a previous study comparing
the expression of 89 miRNAs in GK and outbred Wistar rats,
in which overexpression of miR-29a, miR-29b and miR-29c
was detected in muscle, liver and adipose tissue from
3-month-old GK rats compared with Wistar rats [13]. Our
microarray findings indicate that miR-29a had significantly
different expression between the three strains (adjusted
p=0.0008) only in adipose tissue, and the expression of this
miRNA across these strains followed a BN<GK<WKY
pattern. The disparity of these observations could indicate
that variation in the expression of miR-29a is not due to the
hyperglycaemic phenotype of the GK rat, but represents a
strain/genetic difference in miRNA expression. However,
exposure of 3T3-L1 adipocytes to experimental hypergly-
caemic conditions showed that increased glucose stimulated
the expression of miR-29a, suggesting that this increase in
expression is a genuine observation and not a strain effect.
Because hyperglycaemia is already present in GK
animals and, to some extent (compared with BN levels),
in the WKY strains, it is not possible through a microarray/
qRT-PCR approach to determine whether these differences
in miRNA expression are primary or secondary to the type
2 diabetes phenotype. The effect of glucose levels on the
expression of these miRNAs was evaluated using cultured
adipocytes exposed to hyperglycaemia. We observed
significantly increased expression of miR-222, miR-27a
and the previously observed miR-29a [13], suggesting that,
at least in adipose tissue, increased expression of these
miRNAs may be involved in the initial cellular responses to
hyperglycaemia and be part of the early cellular events
related to the pathogenesis of type 2 diabetes.
The in silico prediction of miRNA target genes and
subsequent functional analysis can provide clues as to what
biological processes may be disrupted by altered miRNA
expression. The MAPK and insulin signalling pathways were
suggested by analysis of the combined list of predicted target
genes of miR-222, miR-27a, miR-10b, miR-103 and miR-
197. Defects in these pathways have been implicated in the
pathogenesis of type 2 diabetes [40–42]. Inferring functional
effects caused by differential miRNA expression is complex
because of the poor overlap between predicted target-gene
lists. In an effort to account for this, we report only the
pathways significant in the analysis of two lists of predicted
target genes generated by the TargetScan and MiRanda
algorithms (ESM Table 2).
In conclusion, these findings provide novel information
on the molecular mechanisms that may account for genetic
loci linked to glucose homeostasis, adiposity [43], lipid
metabolism [44] and metabolite abundance [45] in the GK
strain. This study comprehensively assesses miRNA ex-
pression levels in three insulin target tissues in the GK rat
model of type 2 diabetes. As well as confirming that
miRNA expression is highly tissue-dependent, we found
significant differences between the hyperglycaemic GK rat
and intermediate/normoglycaemic controls in muscle, liver
and adipose tissue. Furthermore, our data suggest that
overexpression of miR-222 and miR-27a and the confir-
mation of miR29a overexpression in adipocytes represent a
response to hyperglycaemia, further implicating altered
microRNA expression in the pathophysiology of type 2
diabetes.
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